

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



APPOINTMENT OF CHIEF FINANCIAL OFFICER

On July 22, 2024, the board of directors (the “**Board**”) of Akeso, Inc. (the “**Company**”) is pleased to announce that Bing C. WANG, Ph.D. (“**Dr. WANG**”) has been appointed as the chief financial officer of the Company.

Dr. Wang is an accomplished biotechnology executive who brings extensive global experience in the biopharmaceutical industry. Prior to joining the Company, Dr. WANG was most recently the chief financial officer of Cellectis S.A., a France-based biopharmaceutical company that develops genome-edited CAR T-cell technologies for cancer immunotherapy. Prior to joining Cellectis S.A., Dr. WANG was the co-founder and chief executive officer at Refuge Biotechnologies, Inc., a biotechnology company that utilizes CRISPR-interference and CRISPR-activation to create therapeutic T-cells. Prior to that, Dr. WANG was a director of US healthcare investment banking at Barclays Capital, where he worked on numerous mergers and acquisitions, corporate finance and other financing transactions for life sciences companies. Dr. WANG also serves on the advisory board of the Healthcare and Pharmaceutical Management Program at Columbia Business School.

Dr. WANG holds a Bachelor of Science degree in applied physics from Columbia University, a Master of Arts degree and a Ph.D. degree in electrical engineering from Princeton University, and a Master of Business Administration degree from Columbia Business School.

The Board warmly welcomes Dr. WANG to join the Company, and looks forward to working with him towards the Company's vision and mission.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, July 22, 2024

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.